Softwr

Healthcare · head to head

Epocrates vs PathAI

Epocrates logo

Epocrates

Healthcare

Mobile clinical reference and decision support app

From
Free
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Epocrates has a free tier, so it costs nothing to try first.
  • Each has a real cost: Epocrates pricing page not publicly accessible; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Epocrates covers Drug Reference, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Epocrates and PathAI actually diverge.

Attributes where Epocrates and PathAI differ
AttributeEpocratesPathAI
Starting priceFreeOn request
Pricing modelfreemiumquote
Free tierYesNo
PlatformsMobileWeb
Founded2000Unknown

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Epocrates

  • Drug Reference
  • Interactions
  • Dosing Calculators
  • Disease Information
  • Medical Procedures
  • Patient Education
  • EHR Systems
  • HIPAA

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Epocrates

  • Patient Carenot PathAI
  • Medical Recordsnot PathAI
  • Practice Managementnot PathAI
  • Telehealthnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Epocrates
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Epocrates
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Epocrates
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Epocrates

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Epocrates

  • Pricing page not publicly accessible

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Epocrates

Free
  • FreeFree
    • Drug references
    • Calculators
    • Interactions
  • Premium$99/year
    • Enhanced content
    • Offline access

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Epocrates if

  • You need drug reference.
  • You want to start without paying.
  • You work on Mobile.
  • You also want interactions.
Epocrates review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Epocrates or PathAI better?
Neither clearly leads. Epocrates starts at Free and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Epocrates or PathAI?
Epocrates has a free tier; the other does not. Paid plans start at Free for Epocrates and On request for PathAI.
Does Epocrates or PathAI run on more platforms?
Epocrates runs on Mobile. PathAI runs on Web.
Can I use Epocrates for free?
Yes. Epocrates has a free tier, so you can try it without paying. PathAI starts at On request.
What is Epocrates best used for?
Epocrates is most often used for patient care, medical records, practice management, telehealth. Of those, patient care and medical records are not what PathAI is typically brought in for.
What can Epocrates do that PathAI cannot?
Epocrates covers Drug Reference, Interactions, Dosing Calculators, Disease Information. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Epocrates: How much does Epocrates cost?

Epocrates pricing information is not available to public access. Users must authenticate or contact the vendor to view pricing details.

Source
PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Epocrates

More on PathAI

Keep looking

Other head to heads